272 related articles for article (PubMed ID: 15183471)
1. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321.
Hsu IC; Bae K; Shinohara K; Pouliot J; Purdy J; Ibbott G; Speight J; Vigneault E; Ivker R; Sandler H
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):751-8. PubMed ID: 20207506
[TBL] [Abstract][Full Text] [Related]
3. Role of isotope selection in long-term outcomes in patients with intermediate-risk prostate cancer treated with a combination of external beam radiotherapy and low-dose-rate interstitial brachytherapy.
Wernicke AG; Shamis M; Yan W; Trichter S; Sabbas AM; Goltser Y; Christos PJ; Brennan JS; Parashar B; Nori D
Urology; 2012 May; 79(5):1098-104. PubMed ID: 22546388
[TBL] [Abstract][Full Text] [Related]
4. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.
Hurwitz MD; Halabi S; Archer L; McGinnis LS; Kuettel MR; DiBiase SJ; Small EJ
Cancer; 2011 Dec; 117(24):5579-88. PubMed ID: 22535500
[TBL] [Abstract][Full Text] [Related]
5. Timing of High-Dose-Rate Brachytherapy With External Beam Radiation Therapy in Patients With Intermediate- and High-Risk Localized Prostate Cancer and Its Effects on Toxicity and Quality of Life: A Randomized Controlled Trial (THEPCA).
Choudhury M; Thomas SS; Cain A; Palvai S; Nageshwaran S; Zhang J; Hayden K; Cain A; Hoskin P; Ahmed I
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):90-99. PubMed ID: 38163520
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
Nishimura S; Ohashi T; Momma T; Sakayori M; Eriguchi T; Tanaka T; Yamashita S; Kosaka T; Oya M; Shigematsu N
Cancer Med; 2018 May; 7(5):1794-1801. PubMed ID: 29577651
[TBL] [Abstract][Full Text] [Related]
7. Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy.
Muñoz Muñoz Ó; Gomis Sellés E; Delgado León BD; Mateos Perez JC; Baeza Trujillo M; Perucha Ortega M; López Guerra JL; Cabrera Roldán P
Clin Transl Oncol; 2024 Apr; 26(4):872-879. PubMed ID: 37672205
[TBL] [Abstract][Full Text] [Related]
8. Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series.
Thomas H; Chen JJ; Abdul-Baki H; Sabbagh A; Shaheen H; Chau OW; Malik N; Ayoub A; Hassanzadeh C; Hsu IC; Mohamad O
Brachytherapy; 2024; 23(2):173-178. PubMed ID: 38160102
[TBL] [Abstract][Full Text] [Related]
9. Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects.
Moll M; Paschen C; Zaharie A; Berndl F; Goldner G
Strahlenther Onkol; 2021 Feb; 197(2):118-123. PubMed ID: 32642874
[TBL] [Abstract][Full Text] [Related]
10. Bladder function after conservative surgery and high-dose rate brachytherapy for bladder-prostate rhabdomyosarcoma.
Lobo S; Gaze MN; Slater O; Hoskin P; Sands G; Sullivan T; Cho A; Eminowicz G; Smeulders N
Pediatr Blood Cancer; 2022 Aug; 69(8):e29574. PubMed ID: 35044080
[TBL] [Abstract][Full Text] [Related]
11. The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions.
Tanaka N; Asakawa I; Katayama E; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
Radiat Oncol; 2014 May; 9():107. PubMed ID: 24885896
[TBL] [Abstract][Full Text] [Related]
12. 21 Gy single fraction prostate HDR brachytherapy: 5-year results of a single institution prospective pilot study.
Salari K; Hazy AJ; Ye H; Sebastian E; Limbacher A; Johnson M; Mitchell B; Thompson AB; Seymour ZA; Nandalur SR; Krauss DJ
Brachytherapy; 2024 Mar; ():. PubMed ID: 38514368
[TBL] [Abstract][Full Text] [Related]
13. Interstitial high-dose-rate brachytherapy as a boost in synchronous prostate and rectal cancer treatment: case report and literature review.
Konat-Bąska K; Chicheł A; Staszek-Szewczyk U; Maciejczyk A; Matkowski R
J Contemp Brachytherapy; 2020 Apr; 12(2):181-187. PubMed ID: 32395143
[TBL] [Abstract][Full Text] [Related]
14. High-dose-rate Brachytherapy Monotherapy in Patients With Localised Prostate Cancer: Dose Modelling and Optimisation Using Computer Algorithms.
Dabic-Stankovic K; Rajkovic K; Stankovic J; Marosevic G; Kolarevic G; Pavicar B
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):378-389. PubMed ID: 38584072
[TBL] [Abstract][Full Text] [Related]
15. Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age.
Armstrong A; Ho H; Mark Tacey M; Bolton D; Chan Y; Tan A; Cham CW; Pham T; McMillan K; Koufogiannis G; Dip G; Manohar P; Guerrieri M; Ng M; Joon DL; Foroudi F; Tan MY; Chao M
J Contemp Brachytherapy; 2024 Feb; 16(1):6-11. PubMed ID: 38584883
[TBL] [Abstract][Full Text] [Related]
16. Association between Site-of-Care and the Cost and Modality of Radiotherapy for Prostate Cancer: Analysis of Medicare Beneficiaries from 2015 to 2017.
Tringale KR; Gennarelli RL; Gillespie EF; Mitchell AP; Zelefsky MJ
Cancer Invest; 2021 Feb; 39(2):144-152. PubMed ID: 33416007
[TBL] [Abstract][Full Text] [Related]
17. Brachytherapy: The urologist opinion.
Pinto F; Russo P
Urologia; 2024 Feb; 91(1):5-7. PubMed ID: 38362868
[TBL] [Abstract][Full Text] [Related]
18. Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique.
Murray L; Henry A; Hoskin P; Siebert FA; Venselaar J;
Radiother Oncol; 2014 Feb; 110(2):213-28. PubMed ID: 24485765
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Survival of a Patient With Anaplastic Thyroid Carcinoma Treated With Hypofractionated Radiotherapy: A Case Report.
Tanaka M; Hatayama Y; Kawaguchi H; Fujioka I; Aoki M
Cureus; 2024 Mar; 16(3):e56689. PubMed ID: 38646274
[TBL] [Abstract][Full Text] [Related]
20. Cryotherapy for primary treatment of prostate cancer: intermediate term results of a prospective study from a single institution.
Rodríguez SA; Arias Fúnez F; Bueno Bravo C; Rodríguez-Patrón Rodríguez R; Sanz Mayayo E; Palacios VH; Burgos Revilla FJ
Prostate Cancer; 2014; 2014():571576. PubMed ID: 24693437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
